AbbVie News and Activities

Presence

AbbVie operates as a pharmaceutical company that actively develops and markets advanced therapies and medicines, primarily targeting chronic autoimmune diseases, oncology, neuroscience, and virology sectors. Its products aim to address some of the world's most complex and serious diseases, serving both healthcare professionals and patients.

AbbVie products and services overview:

Immunology
Oncology
Neuroscience
Virology
Eye care
Aesthetics

2024 Revenue: Approximately $50 billion

Employees: 47,000

AbbVie is one of the...

AbbVie is a company listed under the stock ticker ABBV (US).

AbbVie has a direct presence in 21 countries.

AbbVie has 32 subsidiaries including AbbVie APAC, AbbVie Australia and AbbVie Belgium.

They are in:

Acquisition, funding and merger involving AbbVie.

AbbVie has acquired Cerevel Therapeutics (posted on August 5 2024).
AbbVie has acquired Landos Biopharma (posted on May 25 2024).
AbbVie has announced the acquisition of ImmunoGen (posted on November 30 2023).

Executives

View the org chart displaying its 258 main executives

Most searched biographies at AbbVie

Popular executive movements at AbbVie

Thomas Falk has joined the company as Independent Director (posted on May 14 2025).
Glenn Tilton, Director, will retire on Jul. 1, 2025 (posted on February 16 2025).
Robert Michael who is Chief Executive Officer and Director, will become Chief Executive Officer and Chairman of the Board on Jul. 1, 2025 (posted on February 16 2025).

Click here to view some more movements at AbbVie

Create your alert
to follow the executive moves at AbbVie.